Budget Impact Models

Budget Impact Models

The RXA Budget Impact Model enables pharmaceutical companies to use the NHS’s own data to produce realistic and plausible cost saving prescribing switch strategies.

With the RXA Budget Impact model you can:

  • Create summary overviews at annual and portfolio levels
  • Drill down to underlying detailed product-specific calculations
  • Use tables, charts and maps in the purpose-built dashboard to provide extensive, highly visual and easy to interpret analytics
  • Make on the spot adjustments of model parameters – (E.g. switch %) via slider controls
  • Automatically rank the top ‘X’ GP practices to target
  • Create outputs to leave behind after meetings – Including CCG or GP practice level branded reports containing details of identified cost savings
We make analytics simple
Request your demonstration today

“Fantastic customer service, any requests from us to fine tune the functionality or appearance of the product is done in most cases on the same day as the request.”

National Sales Manager, UK Pharmaceutical Company

“I am regularly told by my sales team that Inspiremed’s software is one of the best tools in sales, measurement and planning that they’ve ever used.”

National Sales Manager, Leading UK Pharmaceutical Company

“I am extremely happy with the model and with the working relationship we have with Inspiremed.”

Country Manager UK, Leading Diagnostics Company

“RX Analyser is an extremely intuitive tool with numerous beneficial features.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“Working with Inspiremed is a great partnership experience and they make sure they understand your business, the industry that you are in and what you want to achieve in the use of the product.”

National Sales Manager, UK Pharmaceutical Company

“I use the data from RXA Budget Impact Model daily. It is the core of everything we do! I cannot recommend the model more. It has had a substantial impact on our business across the board and I would not be without it.”

Country Manager UK, Leading Diagnostics Company

Sign up for added insights